Posted by Michael Wonder on 22 Aug 2022
European Medicines Agency accepts rezafungin marketing authorisation application for the treatment of invasive candidiasis
22 August 2022 - The EMA filing is supported by the pivotal ReSTORE Phase 3 clinical trial results, where rezafungin demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidaemia and/or invasive candidiasis.
Mundipharma today announced that the EMA has accepted the marketing authorisation application for rezafungin for the treatment of invasive candidiasis in adult patients.
